Clinical Trial: Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison with the Reference Drug

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06834100) titled 'Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison with the Reference Drug' on Feb. 13.

Brief Summary: Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug

Study Start Date: Feb. 12

Study Type: INTERVENTIONAL

Condition: Infections Meningococcal

Intervention: DRUG: polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y

Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site.

Group 2 (n = 40) will receive Menactra(R) at a dose of 0.5 mL intramuscularly int...